New radiosynthesis of 2-deoxy-2-[18F]fluoroacetamido-d-glucopyranose and its evaluation as a bacterial infections imaging agent

Martínez, Miguel E.; Kiyono, Yasushi; Noriki, Sakon; Inai, Kei; Mandap, Katheryn S.; Kobayashi, Masato; Mori, Tetsuya; Tokunaga, Yuji; Tiwari, Vijay N.; Okazawa, Hidehiko; Fujibayashi, Yasuhisa; Ido, Tatsuo

doi:10.1016/j.nucmedbio.2011.02.006

Cited by 26 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 18 F]FAG is 2-deoxy-2-[ 18 F]fluoroacetamido-D-glucopyranose and was successfully used to identify E. coli in rat models and to make a discrimination of sterile inflammation from infection. Uptake data were confirmed by histological analysis [121].…”

Section: Amino Sugarsmentioning

confidence: 83%

New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)

Ankrah

Klein

Elsinga

2018

CPD

View full text Add to dashboard Cite

Diabetic Foot Infections (DFIs) are associated with increased morbidity, an economic burden on patients, their families and healthcare systems and increased mortality. Early diagnosis with prompt, appropriate and adequate treatment of the infected diabetic foot is crucial. The determination of DFIs, however, may be quite perplexing and invasive. Imaging is useful in the evaluation of certain cases of DFIs, especially in suspected instances with no overt clinical features, or in the diagnosis of osteomyelitis. Nuclear medicine imaging is currently used in the evaluation of DFIs; however, like all the imaging techniques now available, it has its limitations. Several radiopharmaceuticals presently available play useful roles in the management of DFIs, while new ones are being evaluated. Optical imaging techniques have recently demonstrated promising results in the evaluation of many infections including DFIs. Using the same molecule, a tracer can be labeled with a radioisotope or an optical imaging dye. This enables infections to be evaluated both pre- and intra-operatively when surgery is required in their management. In some cases, tracers have been simultaneously labeled with both a radioisotope and an optical imaging dye to produce a hybrid tracer. These new tracers potentially provide powerful and new opportunities in the management of DFIs. In this review, we briefly examine tracers that have been used in the evaluation of the infected diabetic foot. We then explore the potential of new imaging tracers currently under development for infection that may be useful in the management of DFIs.

show abstract

Section: Amino Sugarsmentioning

confidence: 83%

New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)

Ankrah

Klein

Elsinga

2018

CPD

View full text Add to dashboard Cite

show abstract

“…Several other studies have demonstrated similar results, but always in animal models [29,30]. In addition, other sugars such as 18 F-fluoromaltohexaose (FMH) [31], 6 -18 F-fluoromaltotriose and 18 F-fluoroacetamido-d-glucopyranose (FAG), [32] were revealed to be sensitive and specific radiopharmaceuticals for the detection of E. coli [33]. In addition, a new Gram-negative bacterial infection-specific radiopharmaceutical has been developed: 99m Tc-polymyxin B.…”

Section: Imaging Bacteria In Animal Modelsmentioning

confidence: 84%

Imaging Bacteria with Radiolabelled Probes: Is It Feasible?

Artiko

Conserva

Ferro-Flores

et al. 2020

JCM

View full text Add to dashboard Cite

Bacterial infections are the main cause of patient morbidity and mortality worldwide. Diagnosis can be difficult and delayed as well as the identification of the etiological pathogen, necessary for a tailored antibiotic therapy. Several non-invasive diagnostic procedures are available, all with pros and cons. Molecular nuclear medicine has highly contributed in this field by proposing several different radiopharmaceuticals (antimicrobial peptides, leukocytes, cytokines, antibiotics, sugars, etc.) but none proved to be highly specific for bacteria, although many agents in development look promising. Indeed, factors including the number and strain of bacteria, the infection site, and the host condition, may affect the specificity of the tested radiopharmaceuticals. At the Third European Congress on Infection/Inflammation Imaging, a round table discussion was dedicated to debate the pros and cons of different radiopharmaceuticals for imaging bacteria with the final goal to find a consensus on the most relevant research steps that should be fulfilled when testing a new probe, based on experience and cumulative published evidence.

show abstract

“…The inflammation model was added to evaluate if the imaging agent was able to distinguish between host tissue inflammatory lesions and bacterial infection. Of the 2 methods typically utilized for creating an inflammation model, ie, injection of heat killed bacteria or turpentine oil, the latter method was chosen to gain supplement information about tracer accumulation in sterile inflammatory lesions absent of bacteria or bacterial components. The same postinoculation time was applied for the turpentine‐induced inflammation in mice to align the inflammatory responses of the sterile and infectious tissue lesions.…”

Section: Resultsmentioning

confidence: 99%

Preclinical evaluation of potential infection‐imaging probe [⁶⁸Ga]Ga‐DOTA‐K‐A9 in sterile and infectious inflammation

Nielsen

Jørgensen

Kyneb

et al. 2018

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The development of bacteria-specific infection radiotracers is of considerable interest to improve diagnostic accuracy and enabling therapy monitoring. The aim of this study was to determine if the previously reported radiolabelled 1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic acid (DOTA) conjugated peptide [ Ga]Ga-DOTA-K-A9 could detect a staphylococcal infection in vivo and distinguish it from aseptic inflammation. An optimized [ Ga]Ga-DOTA-K-A9 synthesis omitting the use of acetone was developed, yielding 93 ± 0.9% radiochemical purity. The in vivo infection binding specificity of [ Ga]Ga-DOTA-K-A9 was evaluated by micro positron emission tomography/magnetic resonance imaging of 15 mice with either subcutaneous Staphylococcus aureus infection or turpentine-induced inflammation and compared with 2-deoxy-2-[ F]fluoro-D-glucose ([ F]FDG). The scans showed that [ Ga]Ga-DOTA-K-A9 accumulated in all the infected mice at injected doses ≥3.6 MBq. However, the tracer was not found to be selective towards infection, since the [ Ga]Ga-DOTA-K-A9 also accumulated in mice with inflammation. In a concurrent in vitro binding evaluation performed with a 5-carboxytetramethylrhodamine (TAMRA) fluorescence analogue of the peptide, TAMRA-K-A9, the microscopy results suggested that TAMRA-K-A9 bound to an intracellular epitope and therefore preferentially targeted dead bacteria. Thus, the [ Ga]Ga-DOTA-K-A9 uptake observed in vivo is presumably a combination of local hyperemia, vascular leakiness and/or binding to an epitope present in dead bacteria.

show abstract

New radiosynthesis of 2-deoxy-2-[18F]fluoroacetamido-d-glucopyranose and its evaluation as a bacterial infections imaging agent

Cited by 26 publications

References 22 publications

New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)

New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)

Imaging Bacteria with Radiolabelled Probes: Is It Feasible?

Preclinical evaluation of potential infection‐imaging probe [⁶⁸Ga]Ga‐DOTA‐K‐A9 in sterile and infectious inflammation

Contact Info

Product

Resources

About

New radiosynthesis of 2-deoxy-2-[18F]fluoroacetamido-d-glucopyranose and its evaluation as a bacterial infections imaging agent

Cited by 26 publications

References 22 publications

New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)

New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)

Imaging Bacteria with Radiolabelled Probes: Is It Feasible?

Preclinical evaluation of potential infection‐imaging probe [68Ga]Ga‐DOTA‐K‐A9 in sterile and infectious inflammation

Contact Info

Product

Resources

About

Preclinical evaluation of potential infection‐imaging probe [⁶⁸Ga]Ga‐DOTA‐K‐A9 in sterile and infectious inflammation